Causality Assessment in Drug-Induced Liver Injury

Paul H Hayashi

doi:10.1055/s-0029-1240003

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2009; 29(4): 348-356
DOI: 10.1055/s-0029-1240003

Causality Assessment in Drug-Induced Liver Injury

Paul H. Hayashi¹

¹UNC Liver Program, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina

Abstract

ABSTRACT

Assigning causality in drug-induced liver injury (DILI) due to a particular medication or herbal and dietary supplement relies on clinical history, exclusion of competing causes, prior reports of DILI, and judgment—no objective laboratory or histological tests exist to confirm a diagnosis of suspected DILI. Current causality assessment instruments are based on algorithmic scoring systems but are not widely used. Expert opinion remains the gold standard, but is cumbersome and has limited reproducibility. The lack of a valid and widely available causality assessment method hinders the identification of genetic and biochemical markers that may help better define DILI. Emerging technologies in pharmacogenomics and toxicogenomics may identify such markers if well-defined DILI cases and controls can provide tissue samples for analysis. In this article, current causality assessment instruments, including expert opinion, are discussed, and the necessary features for an improved instrument are provided.

KEYWORDS

Hepatotoxicity - dietary supplements - expert opinion - adverse drug reactions

Volltext

Referenzen

REFERENCES

1 Temple R J. Hepatotoxicity through the years: Impact on the FDA. Available at: http://www.fda.gov/cder/livertox/Presentations/im1389/sld002.htm Accessed May 23, 2009
2 Temple R J, Himmel M H. Safety of newly approved drugs: implications for prescribing. JAMA. 2002; 287(17) 2273-2275
3 Lee W M, Squires Jr R H, Nyberg S L, Doo E, Hoofnagle J H. Acute liver failure: Summary of a workshop. Hepatology. 2008; 47(4) 1401-1415
4 Bissell D M, Gores G J, Laskin D L, Hoofnagle J H. Drug-induced liver injury: mechanisms and test systems. Hepatology. 2001; 33(4) 1009-1013
5 Stephens M D. The diagnosis of adverse medical events associated with drug treatment. Adverse Drug React Acute Poisoning Rev. 1987; 6(1) 1-35
6 Arimone Y, Miremont-Salamé G, Haramburu F et al.. Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol. 2007; 64(4) 482-488
7 Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993; 46(11) 1331-1336
8 Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46(11) 1323-1330
9 Maria V A, Victorino R M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997; 26(3) 664-669
10 Watkins P B, Seeff L B. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006; 43(3) 618-631
11 Fontana R J, Watkins P B, Bonkovsky H L DILIN Study Group et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32(1) 55-68
12 Andrade R J, Lucena M I, Perez-Moreno J M et al.. Drug-induced hepatotoxicity: preliminary results from a surveillance program in south Spain. J Hepatol. 1997; 26(suppl 1) 297
13 Chalasani N, Fontana R J, Bonkovsky H L Drug Induced Liver Injury Network (DILIN) et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135(6) 1924-1934, 1934, e1–e4
14 Witts L J. Adverse reactions to drugs. BMJ. 1965; 2(5470) 1081-1086
15 Naranjo C A, Busto U, Sellers E M et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2) 239-245
16 Kramer M S, Leventhal J M, Hutchinson T A, Feinstein A R. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979; 242(7) 623-632
17 Busto U, Naranjo C A, Sellers E M. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol. 1982; 13(2) 223-227
18 García-Cortés M, Lucena M I, Pachkoria K, Borraz Y, Hidalgo R, Andrade R J. Spanish Group for the Study of Drug-induced Liver Disease (grupo de Estudio para las Hepatopatías Asociadas a Medicamentos, Geham) . Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008; 27(9) 780-789
19 Danan G. Hepatology Working Group . Causality assessment of drug-induced liver injury. J Hepatol. 1988; 7(1) 132-136
20 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11(2) 272-276
21 Rochon J, Protiva P, Seeff L B Drug-Induced Liver Injury Network (DILIN) et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology. 2008; 48(4) 1175-1183
22 Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001; 33(1) 308-310
23 Nesher G, Dollberg L, Zimran A, Hershko C. Hepatosplenic peliosis after danazol and glucocorticoids for ITP. N Engl J Med. 1985; 312(4) 242-243
24 Lasser K E, Allen P D, Woolhandler S J, Himmelstein D U, Wolfe S M, Bor D H. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287(17) 2215-2220
25 Aithal G P, Rawlins M D, Day C P. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol. 2000; 33(6) 949-952
26 Lucena M I, Camargo R, Andrade R J, Perez-Sanchez C J, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001; 33(1) 123-130
27 Arimone Y, Bégaud B, Miremont-Salamé G et al.. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol. 2005; 61(3) 169-173
28 Graham B, Regehr G, Wright J G. Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol. 2003; 56(12) 1150-1156
29 Brinker A D, Wassel R T, Lyndly J et al.. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology. 2009; 49(1) 250-257
30 Rockey D C, Seeff L B, Freston J et al.. Comparison between expert opinion and RUCAM for assignment of causality in drug-induced liver injury. Gastroenterology. 2007; 132(4) A-773
31 Arimone Y, Bégaud B, Miremont-Salamé G et al.. A new method for assessing drug causation provided agreement with experts' judgment. J Clin Epidemiol. 2006; 59(3) 308-314
32 Uusimaa J, Hinttala R, Rantala H et al.. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia. 2008; 49(6) 1038-1045
33 Mallal S, Nolan D, Witt C et al.. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359(9308) 727-732
34 Hetherington S, Hughes A R, Mosteller M et al.. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002; 359(9312) 1121-1122
35 Donaldson P T, Bhatnagar P, Graham J et al.. Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor. Hepatology. 2008; 48(Suppl) 396A
36 Lucena M I, García-Cortés M, Cueto R, Lopez-Duran J, Andrade R J. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008; 22(2) 141-158
37 Kleiner D E, Chalasani N, Conjeevaram H et al.. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH Drug-Induced Liver Injury Network (DILIN) Study. Gastroenterology. 2007; 132(4) A-773
38 Zimmerman H J. The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, PA; Lipponcott Williams & Wilkins 1999
39 Rahmat J, Gelfand R L, Gelfand M C, Winchester J F, Schreiner G E, Zimmerman H J. Captopril-associated cholestatic jaundice. Ann Intern Med. 1985; 102(1) 56-58
40 Balistreri W F. Drug Induced Liver Injury in Children. NIH Workshop on Drug-Induced Liver Injury: Standardization of Nomenclature and Causality Assessment 2008: 25-26
41 Squires Jr R H, Shneider B L, Bucuvalas J et al.. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr. 2006; 148(5) 652-658
42 Kearns G L, Abdel-Rahman S M, Alander S W, Blowey D L, Leeder J S, Kauffman R E. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003; 349(12) 1157-1167

Paul H HayashiM.D. M.P.H.

UNC Liver Program, Division of Gastroenterology and Hepatology

CB#7584, 8011 Burnett-Womack Bldg., Chapel Hill, NC 27599-7584

eMail: paul_hayashi@med.unc.edu